Abstracts tagged "Denosumab and osteoporosis"

Abstract Number: 334 • 2017 ACR/ARHP Annual Meeting
Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals
Nouman A. Syed, Mohammed Wiqar, Douglas Einstadter and Marina N. Magrey, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Denosumab (Dmab) is an antiresorptive agent with an approximate half-life of 26 days and according to the prescribing information the recommended dose is 60…
Abstract Number: 352 • 2016 ACR/ARHP Annual Meeting
Can Lumbar Spine Bone Mineral Density Predict Readmission in Denosumab-Treated Chronic Kidney Disease Patients?
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., YC Chen, Kaohsiung County, Taiwan
Background/Purpose: This study investigated whether bone mineral density (BMD) affects readmission risk in patients with CKD who received denosumab therapy. Methods: All subjects underwent dual…
Abstract Number: 353 • 2016 ACR/ARHP Annual Meeting
Changes in Femoral Neck Bone Mineral Density Inverse Correlate with Egfr in Denosumab Treated Osteoporosis Patients? a Hospital-Based Analysis
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., YC Chen, Kaohsiung County, Taiwan
Background/Purpose: This study investigated the effect of different severities of CKD on bone mineral density (BMD) in patients treated with denosumab. Methods: This study was…
Abstract Number: 345 • 2015 ACR/ARHP Annual Meeting
Relationship Between Total Hip BMD T-Score and Incidence of Nonvertebral Fracture with up to 8 Years of Denosumab Treatment
S Ferrari¹, C Libanati², CJF Lin², S Adami³, JP Brown⁴, F Cosman⁵, E Czerwinski⁶, LH de Gregório⁷, J Malouf⁸, J-Y Reginster⁹, NS Daizadeh², A Wang², RB Wagman² and EM Lewiecki¹⁰, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of Verona, Verona, Italy, ⁴Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ⁵Helen Hayes Hospital, West Haverstraw, NY, ⁶Krakow Medical Center, Krakow, Poland, ⁷CCBR, Rio de Janeiro, Brazil, ⁸Universitat Autònoma de Barcelona, Barcelona, Spain, ⁹University of Liège, Liège, Belgium, ¹⁰New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Background/Purpose: The relationship between BMD T-score and fracture risk has not been established in patients on therapy. We previously reported that denosumab (DMAb) treatment over…
Abstract Number: 898 • 2015 ACR/ARHP Annual Meeting
A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate
PD Miller¹, N Pannacciulli², JP Brown³, E Czerwinski⁴, BS Nedergaard⁵, MA Bolognese⁶, J Malouf⁷, HG Bone⁸, JY Reginster⁹, A Singer¹⁰, C Wang², RB Wagman² and SR Cummings¹¹, ¹Colorado Center for Bone Research, Lakewood, CO, ²Amgen Inc., Thousand Oaks, CA, ³Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ⁴Krakow Medical Center, Krakow, Poland, ⁵Center for Clinical and Basic Research, Aalborg, Denmark, ⁶The Bethesda Health Research Center, Bethesda, MD, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Michigan Bone and Mineral Clinic, Detroit, MI, ⁹University of Liège, Liège, Belgium, ¹⁰Georgetown University Medical Center, Washington, DC, ¹¹San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA
Background/Purpose: Oral bisphosphonates are the most common osteoporosis treatment, but inconvenient dosing regimens and side effects lead to low adherence. Less frequently dosed bisphosphonates, eg,…
Abstract Number: 2257 • 2014 ACR/ARHP Annual Meeting
How Does Non-Compliance to Prolia ® (DENOSUMAB) Impact the Change in Bone Mineral Density (BMD) in Osteoporotic Patients?
Aashish Kalani¹, Matt Wong-Pack¹, Jacob Hordyk², Arthur N. Lau³, George Ioannidis⁴, Robert Bensen⁵, William G. Bensen⁶ and Jonathan D. Adachi¹, ¹McMaster University, Hamilton, ON, Canada, ²University of Ottawa, Hamilton, ON, Canada, ³Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: Denosumab (Prolia®) has shown to be a safe and efficacious therapy for osteoporotic patients in many clinical trials. Unfortunately, few studies have explored its effectiveness…
Abstract Number: 2267 • 2014 ACR/ARHP Annual Meeting
Percentage of Women Achieving Non-Osteoporotic BMD T-Scores at the Spine and Hip over 8 Years of Denosumab Treatment
S. Ferrari¹, C. Libanati², C.J.F Lin², S. Adami³, J.P. Brown⁴, F. Cosman⁵, E. Czerwinski⁶, L.H. de Gregório⁷, J. Malouf⁸, J.-Y. Reginster⁹, N.S. Daizadeh², A. Wang², R.B. Wagman², E.M. Lewiecki¹⁰ and S. Cummings¹¹, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of Verona, Verona, Italy, ⁴Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada, ⁵Helen Hayes Hospital, West Haverstraw, NY, ⁶Krakow Medical Center, Krakow, Poland, ⁷CCBR, Rio de Janeiro, Brazil, ⁸Universitat Autònoma de Barcelona, Barcelona, Spain, ⁹University of Liège, Liège, Belgium, ¹⁰New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ¹¹San Francisco Coordinating Center, CPMC Research Institute, and UCSF, San Francisco, CA
Background/Purpose: Guidelines for the treatment of chronic conditions such as hypertension and diabetes include specific biomarker targets. This differs from osteoporosis treatment guidelines, which currently…
Abstract Number: 1238 • 2013 ACR/ARHP Annual Meeting
Persistence At 12 Months With Denosumab (Prolia^®) In Postmenopausal Women With Osteoporosis: Interim Results From a Prospective Observational Study
Stuart L. Silverman¹, Ethel Siris², David L. Kendler³, Dea Belazi⁴, Jacques P. Brown⁵, Deborah T. Gold⁶, E. Michael Lewiecki^7,8, Alexandra Papaioannou⁹, Christine Simonelli¹⁰, Irene Ferreira¹¹, Paula Dakin¹², Suresh Siddhanti¹², Bradley Stolshek¹² and Christopher Recknor¹³, ¹Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA, ²Columbia University, New York, NY, ³University of British Columbia, Vancouver, BC, Canada, ⁴AlchemiPharma LLC, Wayne, PA, ⁵CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁶Duke University Medical Center, Durham, NC, ⁷University of New Mexico School of Medicine, Albuquerque, NM, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁹Geriatric Medicine, McMaster University, Hamilton, ON, Canada, ¹⁰Health East Osteoporosis Care, Woodbury, MN, ¹¹Amgen Inc., Cambridge, United Kingdom, ¹²Amgen Inc., Thousand Oaks, CA, ¹³United Osteoporosis Centers, Gainesville, GA
Background/Purpose: Persistence with osteoporosis therapy is important for optimal reduction of fracture risk. Persistence with denosumab was >90% in a randomized clinical trial in women…
Abstract Number: 867 • 2013 ACR/ARHP Annual Meeting
Reduced Hip Cortical Porosity Upon Denosumab Treatment: A Likely Mechanism Contributing To The Reduction Of Hip Fracture Risk In Women With Osteoporosis
R. M. Zebaze¹, C. Libanati², M. R. McClung³, J. R. Zanchetta⁴, D. L. Kendler⁵, A. Høiseth⁶, A. Wang², A. Ghasem-Zadeh¹ and E. Seeman¹, ¹Austin Health, University of Melbourne, Melbourne, Australia, ²Amgen Inc., Thousand Oaks, CA, ³Oregon Osteoporosis Center, Portland, OR, ⁴Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Curato Røntgen, Oslo, Norway
Background/Purpose: Nonvertebral fracture risk is significantly influenced by cortical thickness, area, mass, and porosity because all of these contribute to bone strength. In particular, increased…
Abstract Number: 105 • 2013 ACR/ARHP Annual Meeting
Medication Use With Denosumab (Prolia^®) In a Large Claims Database In The United States
Emily Durden¹, Lung-I Cheng², Elnara Eynullayeva³, Christopher Gregory³ and Bradley Stolshek², ¹Truven Health Analytics, Bethesda, MD, ²Amgen, Inc., Thousand Oaks, CA, ³Truven Health Analytics, Washington, DC
Background/Purpose: Persistence and compliance with osteoporosis therapies is associated with significantly fewer vertebral, nonvertebral and hip fractures. A number of studies have examined medication-taking behavior…
Abstract Number: 1961 • 2012 ACR/ARHP Annual Meeting
In Postmenopausal Women with Osteoporosis, Denosumab Significantly Improved Trabecular Bone Score (TBS), an Index of Trabecular Microarchitecture
Michael McClung¹, Kurt Lippuner², Maria Luisa Brandi³, Jean-Marc Kaufman⁴, Jose R. Zanchetta⁵, Marc-Antoine Krieg⁶, Henry G. Bone⁷, Roland Chapurlat⁸, Didier Hans⁶, Andrea Wang⁹, Jang Yun⁹, Carol Zapalowski⁹ and Cesar Libanati⁹, ¹Oregon Osteoporosis Center, Portland, OR, ²University of Berne, Berne, Switzerland, ³University of Florence, Florence, Italy, ⁴University Hospital of Ghent, Ghent, Belgium, ⁵Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, ⁶Center of Bone Diseases, Lausanne University Hospital, Lausanne, Switzerland, ⁷Michigan Bone and Mineral Clinic, Detroit, MI, ⁸Hôpital Edouard Herriot, Lyon, France, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: The trabecular bone score (TBS), a novel gray-level texture index determined from lumbar spine DXA scans, correlates with 3D parameters of trabecular bone microarchitecture…
Abstract Number: 1977 • 2012 ACR/ARHP Annual Meeting
Relationship Between Baseline Bone Turnover Marker Levels and Bone Mineral Density Changes in Men with Low Bone Mineral Density Receiving Denosumab or Placebo
Eric Orwoll¹, Ugis Gruntmanis², Steven Boonen³, Yu-Ching Yang⁴, Rachel B. Wagman⁴, Jesse W. Hall⁴ and Paul D. Miller⁵, ¹Oregon Health and Science University, Portland, OR, ²Dallas Veterans Affairs Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Leuven University, Leuven, Belgium, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: Denosumab, a fully human monoclonal antibody to RANKL, has been shown to increase bone mineral density (BMD) in postmenopausal women with high or low…
Abstract Number: 824 • 2012 ACR/ARHP Annual Meeting
Progressive Improvements in Cortical Mass and Thickness throughout the Hip Were Observed with Denosumab Treatment in the Freedom Trial
Ken Poole¹, Graham Treece¹, Andrew Gee¹, Jacques P. Brown², Michael McClung³, Andrea Wang⁴ and Cesar Libanati⁴, ¹University of Cambridge, Cambridge, United Kingdom, ²CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ³Oregon Osteoporosis Center, Portland, OR, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Denosumab (a RANK ligand antibody) reduces remodeling, increases bone mineral density, and reduces cortical porosity in postmenopausal women with osteoporosis. In FREEDOM, denosumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].